Sulbactam-durlobactam in combination with aztreonam and carbapenems against carbapenem-resistant Acinetobacter baumannii: an assessment using the MIC-based broth disk elution [PDF]
Journal of Clinical MicrobiologyC. Koenig, D. P. Nicolau, T.E. Asempa
doaj +2 more sources
Pharmacokinetics of sulbactam-durlobactam in patients with <i>Acinetobacter baumannii</i> ventriculitis: a report of two cases. [PDF]
Antimicrob Agents ChemotherABSTRACT Two adult patients with ventriculitis due to Acinetobacter baumannii were treated with intravenous sulbactam-durlobactam as a part of a combination regimen. Penetration into the central nervous system was estimated (by
Pouya N +5 more
europepmc +4 more sources
Case commentary: Uncertainty in evaluating treatment outcomes in carbapenem-resistant acinetobacter baumannii infections [PDF]
, 2021 Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are challenging to treat and associated with poor clinical outcomes. In this issue, sulbactamdurlobactam, a novel b-lactam-b-lactamase inhibitor, was used with cefiderocol to successfully ...
Howard-Anderson J., van Duin D.
core +2 more sources
Antibiotics Usage in Special Clinical Situations [PDF]
, 2023 Medicine and the treatment of infectious diseases are increasingly focused on patient-tailored diagnostics and therapy [...]
Di Bella, Stefano
core +1 more source
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]
J Antimicrob ChemotherAbstract Background and objectives Mycobacterium abscessus has extensive innate and acquired antibiotic resistance resulting in limited antibiotic treatment options and poor clinical outcomes. Currently, the only β-lactam antibiotics with efficacy against M. abscessus are imipenem and cefoxitin.
Patterson-Fahy K +5 more
europepmc +5 more sources
Turning the Tide Against Carbapenem-resistant <i>Acinetobacter baumannii</i>: Advancing Care With Sulbactam-Durlobactam. [PDF]
Open Forum Infect DisSatlin M +3 more
europepmc +3 more sources
A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant [PDF]
, 2021 An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Adams, Mark D +13 more
core +2 more sources
Carbapenemase Inhibitors: Updates on Developments in 2021 [PDF]
, 2022 Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently ...
Allam, Sabine +7 more
core +1 more source
Biochemical exploration of β-lactamase inhibitors [PDF]
, 2023 The alarming rise of microbial resistance to antibiotics has severely limited the efficacy of current treatment options. The prevalence of β-lactamase enzymes is a significant contributor to the emergence of antibiotic resistance.
Debasish Kar, Varshaa Arer
core +1 more source
Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant <i>Acinetobacter baumannii</i> strains. [PDF]
JAC Antimicrob ResistAbstract Background Acinetobacter baumannii is a bacterial pathogen frequently implicated in healthcare-associated infections, with limited effective treatment options due to widespread antibiotic resistance.
Halim J, Bouzo J, Carabetta VJ.
europepmc +3 more sources